<DOC>
	<DOCNO>NCT01273298</DOCNO>
	<brief_summary>Patients chronic obstructive pulmonary disease ( COPD ) great risk suffer disease beta-blockers may indicate effective . Clinicians remain hesitant administer beta-blockers COPD patient fear adverse effect lung function . However , cardioselective beta-blockers therapy lead non-significant worsen rest expiratory flow limitation measure forced expiratory volume one second ( FEV1 ) compare placebo . But , FEV1 appear crude estimate bronchial obstruction COPD . Importantly , effect cardioselective beta-blockers dynamic hyperinflation , subtle marker bronchial obstruction , remain unknown . Thus , prospective placebo-controlled study assess effect short-term cardioselective beta-blocker therapy dynamic hyperinflation patient moderate-to-severe COPD need .</brief_summary>
	<brief_title>Effects Cardioselective Î²-blockers Dynamic Hyperinflation COPD</brief_title>
	<detailed_description>Beta-blockers indicate management numerous medical condition include angina pectoris , myocardial infarction , hypertension , congestive heart failure , cardiac arrhythmia , systemic hypertension , well reduce complication perioperative period . Patients chronic obstructive pulmonary disease ( COPD ) great risk condition may therefore benefit use beta-blockers . Despite clear evidence effectiveness , clinician often hesitant administer beta-blockers COPD patient fear adverse effect lung function . Indeed , pathophysiologic hallmark COPD expiratory flow limitation . Because beta-adrenergic receptor participate bronchial dilatation , review article practice guideline traditionally list asthma COPD relative contraindication beta-blocker use , cite case acute bronchospasm occur beta-blocker exposure . However , cardioselective betablockers 20 time affinity beta-1 receptor beta-2 receptor , theoretically significantly less risk bronchoconstriction . Cardioselective beta-blockers include atenolol , metoprolol , bisoprolol acebutolol . A recent Cochrane analysis document safety cardioselective beta-blockers COPD . Indeed , single dos cardioselective beta-blockers well treatment long duration range 2 day 12 week lead non-significant worsening lung function compare placebo . Expiratory flow limitation commonly assess forced expiratory volume one second ( FEV1 ) . However , FEV1 appear crude estimate bronchial obstruction COPD . Indeed , relationship physiologic impairment , traditionally measure FEV1 , characteristic symptom COPD straightforward . Dyspnea appear related dynamic hyperinflation occur exercise FEV1 measure rest . Lung hyperinflation define abnormal increase volume air remain lung end spontaneous expiration . For example , bronchodilator , generally minimal effect FEV1 COPD , work improve dynamic airway function , allow improve lung empty breath . This allow patient achieve require alveolar ventilation rest exercise lower operating lung volume thus low oxygen cost breathing . Exercise proceed long duration mechanical limitation ventilation reach . Changes dynamic hyperinflation thus representative subtle change bronchial obstruction . Importantly , effect cardioselective beta-blockers dynamic hyperinflation , subtle marker bronchial obstruction , remain unknown . The aim prospective , randomize , double blind crossover study assess effect short-term cardioselective beta-blocker therapy dynamic hyperinflation exercise tolerance symptoms patient moderate-to-severe COPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
	<criteria>age : &gt; 50 year old ; cigarette exposure : &gt; 10 packyear ; moderatetosevere COPD ( Forced expiratory volume one second/Forced vital capacity ( FEV1/FVC ) &lt; 70 % ; FEV1 30 80 % predict ) . previous bronchospasm induce betablockers ; respiratory exacerbation previous 8 week ; longterm oxygen therapy arterial oxygen saturation &lt; 85 % rest ; know coronary artery disease persistent symptom persistent myocardial ischemia cardiac imaging ; leave ventricular ejection fraction &lt; 40 % ; current treatment oral corticosteroid ; intrinsic musculoskeletal abnormality preclude exercise testing ; medical condition patient currently treat betablockers .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>exercise</keyword>
	<keyword>dynamic hyperinflation</keyword>
	<keyword>cardioselective beta blocker</keyword>
</DOC>